ITCI News and Press, Intra-Cellular Therapies Inc.

2024-06-20 15:00:05 ET Graig Suvannavejh from Mizuho Securities issued a price target of $100.00 for ITCI on 2024-06-20 12:10:00. The adjusted price target was set to $100.00. At the time of the announcement, ITCI was trading at $76.06. The overall price target consensus...

2024-06-19 02:08:12 ET Summary Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. I...

2024-06-18 08:06:59 ET More on Intra-Cellular Therapies Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Call Transcript Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy Intra-Cellular: More Upside Possible Even After Positive M...

In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery- Åsberg Depression Rating Sc...

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Office...

2024-05-30 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While it’s always comforting to bank on ideas that the masses believe in, overlooked stocks have their charm too. By targeting enterprises that relatively few investors follow, should th...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and ...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinica...

2024-05-22 01:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...